1H-苯并咪唑-5-醇 | 41292-65-3

• 物质功能分类: 生物 - 细胞培养 - 培养基
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 1H-苯并咪唑-5-醇
• 中文别名: 5-羟基苯并咪唑；5-甲基-1H-茚
• 英文名称: 5-hydroxy-1H-benzimidazole
• 英文别名: 5(6)-hydroxybenzimidazole；5-hydroxybenzimidazole；1H-benzimidazol-5-ol；1H-1,3-benzodiazol-5-ol；3H-benzimidazol-5-ol
• CAS: 41292-65-3
• 化学式: C₇H₆N₂O
• mdl: MFCD02241303
• 分子量: 134.137
• InChiKey: KRKSOBREFNTJJY-UHFFFAOYSA-N

物化性质

• 熔点：
  220-222℃
• 沸点：
  469.1±18.0 °C(Predicted)
• 密度：
  1.434±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  48.9
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-Hydroxybenzimidazole
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-Hydroxybenzimidazole
CAS number: 41292-65-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H6N2O
Molecular weight: 134.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1H-苯并咪唑-5-醇 在 sodium ethanolate 、 palladium diacetate 、 sodium 、 potassium carbonate 、 1,2-双(二苯基膦)乙烷 作用下， 以 四氢呋喃 、 2-甲基四氢呋喃 、 水 、 甲苯 为溶剂， 反应 4.0h， 生成 [1-[2-[5-(3-甲基氧杂环丁烷-3-基甲氧基)苯并咪唑-1-基]喹啉-8-基]哌啶-4-基]胺
  参考文献：
  名称：

  一种治疗白血病药物的制备方法

  摘要：

  本发明涉及一种治疗白血病药物的制备方法，该方法包括以下步骤，步骤1：2‑氯‑8‑三氟甲磺酸基喹啉的制备步骤2：2‑氯‑8(哌啶‑4基)喹啉氨基甲酸叔丁酯的制备步骤3：5‑(3‑甲基氧杂环丁烷‑3‑甲氧基)苯并咪唑的制备步骤4：(1‑{2‑[5‑(3‑甲基‑氧杂环丁烷‑3‑基甲氧基)‑苯并咪唑‑1‑基]‑喹啉‑8‑基}‑哌啶‑4‑基‑氨基甲酸叔丁酯的制步骤5：(1‑{2‑[5‑(3‑甲基‑氧杂环丁烷‑3‑基甲氧基)‑苯并咪唑‑1‑基]‑喹啉‑8‑基}‑4‑氨基哌啶的制备。

  公开号：

  CN107382984B
• 作为产物：
  描述：

  5-甲氧基苯并咪唑 在 氢溴酸 作用下， 以 水 为溶剂， 以51 %的产率得到1H-苯并咪唑-5-醇
  参考文献：
  名称：

  开发用于脑肿瘤 Sigma-2 受体成像的高度特异性 18F 标记放射性配体

  摘要：

  设计并合成了具有 6,7-二甲氧基-1,2,3,4-四氢异喹啉或 5,6-二甲氧基异吲哚啉药效团的新型配体，用于评估其与 sigma-2 (σ 2 ) 受体的结构-活性关系，并开发了这些配体作为合适的 PET 放射性配体。化合物1对 σ 2受体具有纳摩尔级亲和力（K i (σ 1 ) = 2.57 nM） 、高亚型选择性（>2000 倍）以及对 40 种其他受体和转运蛋白的高选择性。制备的放射性配体[ 18 F] 1的放射化学产率为37–54%，放射化学纯度> 99%，摩尔活度为107–189 GBq/μmol。小鼠中的生物分布和阻断研究以及大鼠中的[ 18 F] 1显微 PET/CT 成像表明其与体内σ 2受体具有优异的结合特异性。U87MG 胶质瘤异种移植模型中的 [ 18 F] 1显微 PET/CT 成像显示出清晰的肿瘤可视化，具有高肿瘤摄取和肿瘤背景比。与 CM398 (5 μmol/kg)

  DOI：

  10.1021/acs.jmedchem.3c00735

文献信息

• Cobalamin conjugates for anti-tumor therapy
  申请人：Weinshenker M. Ned

  公开号：US20050054607A1

  公开（公告）日：2005-03-10

  The present invention provides a cobalamin-drug conjugate suitable for the treatment of tumor related diseases. Cobalamin is indirectly covalently bound to an anti-tumor drug via a cleavable linker and one or more optional spacers. Cobalamin is covalently bound to a first spacer or the cleavable linker via the 5′-OH of the cobalamin ribose ring. The drug is bound to a second spacer of the cleavable linker via an existing or added functional group on the drug. After administration, the conjugate forms a complex with transcobalamin (any of its isoforms). The complex then binds to a receptor on a cell membrane and is taken up into the cell. Once in the cell, an intracellular enzyme cleaves the conjugate thereby releasing the drug. Depending upon the structure of the conjugate, a particular class or type of intracellular enzyme affects the cleavage. Due to the high demand for cobalamin in growing cells, tumor cells typically take up a higher percentage of the conjugate than do normal non-growing cells. The conjugate of the invention advantageously provides a reduced systemic toxicity and enhanced efficacy as compared to a corresponding free drug.

  本发明提供了一种适用于治疗肿瘤相关疾病的钴胺素-药物结合物。钴胺素通过可切割的连接剂间接共价结合到抗肿瘤药物上，还可以通过一个或多个可选的间隔物。钴胺素通过其核糖环的5'-OH与第一间隔物或可切割连接剂共价结合。药物通过其现有或添加的功能基团与可切割连接剂的第二间隔物结合。在给药后，结合物与转钴胺素（其任何同工异构体）形成复合物。然后，该复合物结合到细胞膜上的受体并被细胞摄取。一旦进入细胞，细胞内酶将切割结合物，从而释放药物。根据结合物的结构，特定类别或类型的细胞内酶影响切割。由于生长细胞对钴胺素的需求量较高，肿瘤细胞通常摄取结合物的比例高于正常非生长细胞。本发明的结合物与相应的游离药物相比，具有较低的全身毒性和增强的疗效。
• 含苯并杂环结构的酰胺衍生物、组合物和应用
  申请人：中国人民解放军军事科学院军事医学研究院

  公开号：CN111217776A

  公开（公告）日：2020-06-02

  本发明属于医药技术领域，本发明公开了一种含苯并杂环结构的酰胺衍生物、组合物和应用。其中，所述的含苯并杂环结构的酰胺衍生物为结构式I所示的化合物及其非毒性药学上可接受的盐：或，所述的含苯并杂环结构的酰胺衍生物为结构式II所示的化合物或其非毒性药学上可接受的盐：本发明的含苯并杂环结构的酰胺衍生物镇痛活性及对靶标钠离子通道Nav1.7的抑制作用效果好。
• Synthesis and Evaluation of Novel α-Aminoamides Containing Benzoheterocyclic Moiety for the Treatment of Pain
  作者：Kun Tong、Ruotian Zhang、Fengzhi Ren、Tao Zhang、Junlin He、Jingchao Cheng、Zixing Yu、Fengxia Ren、Yatong Zhang、Weiguo Shi

  DOI：10.3390/molecules26061716

  日期：——

  Novel α-aminoamide derivatives containing different benzoheterocyclics moiety were synthesized and evaluated as voltage-gated sodium ion channels blocks the treatment of pain. Compounds 6a, 6e, and 6f containing the benzofuran group displayed more potent in vivo analgesic activity than ralfinamide in both the formalin test and the writhing assay. Interestingly, they also exhibited potent in vitro anti-Nav1

  合成了含有不同苯并杂环部分的新型α-氨基酰胺衍生物，并对其进行了电压门控钠离子通道阻滞了疼痛的治疗的评估。含有苯并呋喃基团的化合物6a，6e和6f在福尔马林试验和扭体试验中均显示出比雷非酰胺更强的体内止痛活性。有趣的是，它们在膜片钳电生理测定中还显示出强大的体外抗Na v 1.7和抗Na v 1.8活性。因此，化合物6a，6e和6f对两种与疼痛有关的Na v具有抑制作用 目标，可以作为镇痛药开发的新线索。
• [EN] 5-(1 H-BENZO[D]IMIDAZO-2-YL)-PYRIDIN-2-AMINE AND 5-(3H-IMIDAZO[4,5-B]PYRIDIN-6-YL)-PYRIDIN-2-AMINE DERIVATIVES AS C-MYC AND P300/CBP HISTONE ACETYLTRANSFERASE INHIBITORS FOR TREATING CANCER<br/>[FR] DÉRIVÉS DE 5-(1 H-BENZO[D]IMIDAZO-2-YL)-PYRIDIN-2-AMINE ET DE 5-(3H-IMIDAZO[4,5-B]PYRIDIN-6-YL)-PYRIDIN-2-AMINE UTILISÉS EN TANT QU'INHIBITEURS D'HISTONE ACÉTYLTRANSFÉRASE DE C-MYC ET P300/CBP POUR LE TRAITEMENT DU CANCER
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2019049061A1

  公开（公告）日：2019-03-14

  The invention is directed to substituted 5-(1H-benzo[d]imidazo-2-yl)- pyridin-2-amine and 5-(3H-imidazo[4,5-b]pyridin-6-yl)-pyridin-2-amine derivatives. Specifically, the invention is directed to compounds according to Formula (lb) wherein R', R2', R3', R4', Rs', R6', R7', and X1' are as defined herein; or a salt thereof including a pharmaceutically acceptable salt thereof. The compounds of the invention decrease MYC protein (c-MYC) in cells and/or inhibit p300/CBP histone acetyltransferase and can be useful in the treatment of cardiac hypertrophy, diabetes, obesity & nonalcoholic fatty liver disease, HIV, polycystic kidney disease, inflammatory diseases, ankylosing spondylitis, psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease, multiple sclerosis, cancer and pre-cancerous syndromes, and diseases associated with dysregulation of Myc or inhibition of p300/CBP histone acetyltransferase. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention still further discloses methods of reducing MYC protein (c-MYC) in cells and inhibiting p300/CBP histone acetyltransferase activity, and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  本发明涉及取代的5-(1H-苯并[d]咪唑-2-基)-吡啶-2-胺和5-(3H-咪唑[4,5-b]吡啶-6-基)-吡啶-2-胺衍生物。具体而言，本发明涉及根据公式(lb)的化合物，其中R'、R2'、R3'、R4'、Rs'、R6'、R7'和X1'按本说明书中定义；或其盐，包括药用可接受的盐。本发明的化合物能够降低细胞中的MYC蛋白（c-MYC）和/或抑制p300/CBP组蛋白乙酰转移酶，可用于治疗心肌肥大、糖尿病、肥胖和非酒精性脂肪肝疾病、HIV、多囊肾疾病、炎症性疾病、强直性脊柱炎、银屑病、银屑病关节炎、类风湿性关节炎、克罗恩病、多发性硬化症、癌症和前癌症综合症，以及与Myc失调或p300/CBP组蛋白乙酰转移酶抑制相关的疾病。因此，本发明进一步涉及包含本发明化合物的药物组合物。本发明还进一步公开了使用本发明的化合物或包含本发明化合物的药物组合物，降低细胞中MYC蛋白（c-MYC）和抑制p300/CBP组蛋白乙酰转移酶活性的方法，以及治疗与之相关的疾病的方法。
• [EN] 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS<br/>[FR] ANALOGUES DE PYRIDAZINE 1,4-DISUBSTITUÉE ET PROCÉDÉS DE TRAITEMENT DE TROUBLES LIÉS À UNE DÉFICIENCE EN SMN
  申请人：NOVARTIS AG

  公开号：WO2014028459A1

  公开（公告）日：2014-02-20

  The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供了一种公式(I)的化合物或其药用可接受的盐；一种制造本发明化合物的方法及其治疗用途。本发明进一步提供了一种药物活性剂的组合物和一种药物组合物。